Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Trastuzumab in breast cancer metastatic setting: a retrospective study of clinical predictors of exceptional responders
Örebro University, School of Medical Sciences.
2019 (English)Independent thesis Basic level (degree of Bachelor), 10 credits / 15 HE creditsStudent thesis
Abstract [en]

Background

Currently,human epidermal growth factor 2(HER2)-positive, metastaticbreast cancer is considered an incurable disease;however, a small group can remain in long-term remission with theuse of anti-HER2 treatment. This small group of exceptional responders may beclinicallycured.

Aim

In this retrospectivecohort study, the aim was to identifythe rate of exceptional respondersto trastuzumab-based therapyand potentialclinical predictive factorsin a consecutive cohortof patients with HER2metastatic breast cancer.

Methods

Electronic medical records from 148patients with HER2-positive metastatic breast cancer that had received trastuzumab as a first line treatmentwereretrospectively evaluated.The patients included had been treated at three different hospitals in Sweden between 2010-2018.

Results

In total, 24 patients (16.2%; 95% Confidence Interval (CI): 10.9 –23.4%) were classified as exceptional responders to trastuzumab-based therapy. Two clinical factors were potentially associated to exceptional responses: complete remission as best response in 1st line treatment was associated to higher probability (Odds Ratio (OR): 7.67; 95% CI: 2.63 -22.33);presence of lymph node metastases with lower probability for exceptional response (OR: 0.35; 95% CI: 0.11 -1.09)

Conclusion

-A meaningful number of patients with HER2-positive metastatic breast cancer are expected to be exceptional responders to trastuzumab-based therapy. The achievementof CRis an important predictive factor for exceptional responses. Additional studies preferably with a uniformand widely accepted definition of exceptional responses are warrantedto confirm our findings and further investigate potential clinical and molecularpredictors.

Place, publisher, year, edition, pages
2019.
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:oru:diva-78032OAI: oai:DiVA.org:oru-78032DiVA, id: diva2:1372428
Subject / course
Medicine
Supervisors
Examiners
Available from: 2019-11-23 Created: 2019-11-23 Last updated: 2019-11-23Bibliographically approved

Open Access in DiVA

fulltext(329 kB)6 downloads
File information
File name FULLTEXT01.pdfFile size 329 kBChecksum SHA-512
d9a7846ffd27b269394426cb477e2725b808a7501183498b0719b522b89df89a8ec787ff9bccd4241a87afd31be2a5cdc4656bb3a9d44979807ef0e06e42b1dc
Type fulltextMimetype application/pdf

By organisation
School of Medical Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 6 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

urn-nbn

Altmetric score

urn-nbn
Total: 9 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf